Industries

SHERIDAN, WYOMING - July 21, 2025 - Dental professionals seeking to preserve patients' natural dentition now have a new tool for proactive care: the KaVo DIAGNOcam Vision Full HD system, designed to enhance early caries detection and treatment planning without the risks associated with radiation. By addressing common diagnostic challenges, this technology aims to set new standards in early caries management and patient communication.

Meeting the Limitations of Traditional Diagnostic Methods

Conventional methods such as bitewing radiography and visual-tactile examinations often fall short in detecting interproximal or secondary caries at early stages. Frequently, lesions either progress unnoticed between check-ups or remain inactive for extended periods, leaving practitioners uncertain about the right course of action. The KaVo DIAGNOcam Vision Full HD responds directly to these gaps.

SHERIDAN, WYOMING – July 21, 2025 – KaVo Dental has launched the DIAGNOcam Vision Full HD, an innovative dental diagnostic device that enables simultaneous capture, presentation, and storage of three diagnostic images in less than one second. Designed to integrate seamlessly into existing clinical workflows, this advanced system supports dental professionals in enhancing diagnostic accuracy while improving patient communication and care.

Revolutionizing Dental Diagnostics with Real-Time Triple Imaging

With the introduction of the DIAGNOcam Vision Full HD, KaVo Dental brings a significant technological advancement to the dental sector. The device combines cutting-edge transillumination and fluorescence technology, allowing for high-definition, radiation-free imaging that supports early caries detection and more effective patient consultations.

Key features of the DIAGNOcam Vision Full HD include:

SHERIDAN, WYOMING - July 21, 2025 - KaVo, a renowned innovator in dental technology, has officially launched the MASTERmatic LUX M45 L High-Speed Handpiece, expanding its MASTER series with a model engineered for advanced precision, improved visibility, and enhanced patient care. The introduction of this high-performance device marks a strategic move to strengthen KaVo's footprint in the competitive market for dental treatment solutions.

Advancing Ergonomics and Patient Safety in Dentistry

With the MASTERmatic LUX M45 L, KaVo is addressing key demands of modern dental practices by combining ergonomic design with cutting-edge technology. According to the company's announcement, the new handpiece is specifically developed to improve access and visibility during procedures, enabling dental professionals to deliver more precise treatments while ensuring maximum patient safety.

SHERIDAN, WYOMING – July 21, 2025 – KaVo Dental underscores its commitment to product quality and customer satisfaction with a comprehensive warranty program and a strong emphasis on the use of original parts for repairs and maintenance. This approach supports dental professionals in maximizing equipment performance, longevity, and operational safety across their practices.

Comprehensive Warranty Secures Product Reliability

KaVo guarantees its handpieces and small equipment when purchased new and unused from authorized KaVo dealers. The manufacturer warranty protects buyers against defects in material and workmanship under normal service conditions for a period of 90 days from the date of sale, starting no later than the dealer’s invoice date.

SHERIDAN, WYOMING - July 21, 2025 - KaVo has strengthened its commitment to environmental responsibility by embedding a comprehensive sustainability program into its corporate strategy and achieving certification under the ISO 14001:2015 environmental management standard. The initiative underscores KaVo's focus on operational sustainability, resource efficiency, and long-term environmental impact reduction.

ISO 14001 Certification Marks a Milestone in KaVo's Environmental Journey

KaVo's multi-stage environmental plan, integrated with its corporate policy and management systems, received certification in accordance with DIN EN ISO 14001:2015. This achievement reflects the company's proactive approach to environmental management and positions it for further sustainability advancements.

SHERIDAN, WYOMING - July 21, 2025 - KaVo, the renowned dental technology manufacturer based in Biberach, Germany, is reaffirming its long-standing commitment to excellence-this time by embedding sustainability at the core of its corporate strategy. With a newly certified environmental management system and a multi-stage sustainability plan, KaVo is strengthening its role as a responsible industry leader focused on environmental protection and operational efficiency.

Certified Environmental Management Anchored in Corporate Policy

KaVo has successfully completed certification under DIN EN ISO 14001:2015, the internationally recognized standard for environmental management systems. This achievement underscores the company's commitment to structured, accountable, and transparent sustainability practices.

KaVo Elevates EXPERT Series with Enhanced Safety, Durability, and PerformanceSHERIDAN, WYOMING - July 21, 2025 - KaVo, a trusted leader in dental instrument innovation, has introduced an extensive update to its established EXPERT series, reinforcing its commitment to high-quality, user-focused solutions for dental professionals worldwide. With this enhancement, the EXPERTmatic and EXPERTtorque lines now feature advanced safety measures, improved durability, and increased performance-aligning with KaVo's longstanding promise of "Dental Excellence."

EXPERT Series Evolution to Meet Modern Practice Demands

For years, KaVo's EXPERT series has been synonymous with reliability, intelligent design, and operational efficiency. By integrating new features and technological upgrades, KaVo aims to ensure these instruments continue to exceed professional expectations amid the evolving demands of modern dental practice.

SHERIDAN, WYOMING – July 21, 2025 – KaVo has introduced the SURGmatic™ S15 L Pro high-speed contra-angle surgical handpiece, positioning itself at the forefront of surgical innovation with a product designed to meet a broad spectrum of clinical demands. Engineered for both surgical and non-surgical applications, the SURGmatic S15 L Pro underscores KaVo’s commitment to performance, reliability, and operator efficiency in demanding clinical environments.

Enhanced Performance for Complex Surgical Applications

With a gear ratio of 1:5 and rotational speeds reaching up to 200,000 rpm, the SURGmatic S15 L Pro is tailored for procedures requiring precision and power. According to KaVo, this capability enables clinicians to operate effectively even during the most challenging interventions — a strategic advantage in fast-paced surgical settings.

Key features of the SURGmatic S15 L Pro include:

SHERIDAN, WYOMING - July 21, 2025 - Carestream Dental has secured a significant milestone as its CS 9600 and CS 8200 3D Family CBCT systems have been officially certified by the Digital Dentistry Society (DDS). As the first-and currently only-CBCT imaging systems to earn this distinguished certification, the recognition underscores Carestream Dental's leadership in digital dental innovation and clinical excellence.

A Rigorous Certification Validates Clinical and Technological Leadership

The DDS Product Certification is granted exclusively after a comprehensive, months-long evaluation by a panel of globally renowned experts in digital dentistry. The certification process rigorously assesses products based on three key pillars:

SHERIDAN, WYOMING - July 21, 2025 - Sensei, the practice and patient management brand of Carestream Dental, has announced a strategic integration with DentalMonitoring, a global leader in AI-powered remote monitoring solutions for orthodontics. The collaboration, revealed during the 2025 American Association of Orthodontists (AAO) Annual Session in Philadelphia, marks a pivotal move in expanding digital orthodontic care with advanced clinical oversight, enhanced operational efficiency, and increased patient engagement.

Driving Growth Through Seamless Digital Integration

Unveiled as part of DentalMonitoring's new Integration Partner Program, this partnership positions Sensei Cloud Ortho-Sensei's cloud-based practice management platform for orthodontists-within an innovative ecosystem designed to streamline practice operations and optimize patient monitoring.

SHERIDAN, WYOMING - July 21, 2025 - Carestream Dental has reaffirmed its strategic commitment to innovation and customer partnership as dental professionals navigate a turbulent global market. In a direct message to the industry, CEO Lisa Ashby underscored the company's dedication to supporting practices facing inflation, market volatility, and shifting regulatory landscapes.

Ashby's statement highlights Carestream Dental's ongoing efforts to balance technological advancement with financial accessibility - a focus that positions the company as a resilient partner in times of economic uncertainty.

A Steadfast Commitment to Innovation

SHERIDAN, WYOMING - July 21, 2025 - Carestream Dental showcased its latest innovations in clinical productivity and patient care at IDS 2025 in Cologne, Germany, under the theme "Delivering What's Next." The company's presentation at Hall 11.1, C010, reflected its longstanding commitment to advancing dental technology and empowering practitioners worldwide.

Innovation That Builds on a Century of Leadership

"Asking the right questions and delivering the best solutions has made Carestream Dental a market leader for more than a century and has helped our customers deliver the best in oral healthcare," stated Lisa Ashby, CEO of Carestream Dental.

SHERIDAN, WYOMING – July 21, 2025 – Illinois' life sciences industry continues to demonstrate resilience and growth, underlining the state's standing as a regional powerhouse in biopharma employment. According to 2024 data from BIO and TEConomy Partners, Illinois employed 93,402 bioscience professionals across 4,926 businesses, marking a 7.5% increase in employment since 2019 — a growth trajectory that positions the state as a key hub within the BioMidwest Hotbed.

Steady Hiring Momentum in 2025

SHERIDAN, WYOMING – July 21, 2025 – Facing industry-wide uncertainty and hiring slowdowns, biopharma companies are increasingly turning to fractional roles to fill critical talent gaps—an emerging trend reshaping workforce strategies across the sector. Recent insights from recruiters and professionals reveal a growing openness to flexible, project-based roles that offer companies agility while providing experienced professionals with continued engagement in the field.

Fractional Work Gains Traction Amid Market Challenges

A July LinkedIn poll conducted by BioSpace indicated that 22% of respondents have experience with fractional roles, while an additional 54% are considering them. This shift is driven largely by a tightening job market and prolonged hiring timelines.

SHERIDAN, WYOMING – July 21, 2025 – The latest generation of biotech unicorns is navigating a challenging financial landscape, as AI-powered drug discovery ventures encounter tight investment conditions and a shrinking pool of exit opportunities. While their billion-dollar valuations once promised swift IPOs, today's market demands more strategic flexibility, operational discipline, and differentiated technologies.

Valuations Under Pressure in a Binary Outcome Industry

Valuations in biotech remain inherently speculative, often hinging on clinical outcomes that may take over a decade to materialize. “Biotech valuations remain speculative bets on binary clinical outcomes that typically take 10 to 15 years to materialize,” said Kaz Helal, senior biotech analyst at PitchBook. “Most biotechs only prove their true worth when Big Pharma writes the check at exit.”

SHERIDAN, WYOMING – July 21, 2025 – In a market often defined by bold strategies and high-stakes negotiations, five biotech CEOs have recently steered their companies into billion-dollar acquisitions — and each of them is a woman. These industry leaders not only shaped breakthrough therapies but also orchestrated some of the most high-profile M&A deals of recent years, underscoring the growing influence of women in biotech leadership.

Intra-Cellular Therapies: Sharon Mates’ Strategic Vision Realized in $14.6 Billion J&J Acquisition

Sharon Mates, founder, chairman, and CEO of Intra-Cellular Therapies, led the company from its 2002 inception to this year’s landmark $14.6 billion acquisition by Johnson & Johnson. Mates guided Intra-Cellular through key milestones, including FDA approvals for its atypical antipsychotic Caplyta in 2019 and 2021.

SHERIDAN, WYOMING – July 21, 2025 – Acadia Pharmaceuticals has presented an ambitious vision to transform itself from a small biotech player into a recognized powerhouse, leveraging a sharpened leadership focus and a pipeline with multi-billion-dollar potential. Marking a milestone in its 32-year history, the company recently hosted its inaugural R&D Day, unveiling strategic plans aimed at driving up to $12 billion in annual pipeline-driven revenue.

Leadership Duo Drives Strategic Realignment

SHERIDAN, WYOMING – July 21, 2025 – The American Diabetes Association’s 2025 Scientific Sessions spotlighted the evolving priorities of obesity drug development, emphasizing muscle preservation, improved tolerability, and novel molecular targets. With global analysts projecting the anti-obesity market to exceed $150 billion annually by the early 2030s, biopharmaceutical companies are racing to innovate beyond first-generation GLP-1 therapies.

Obesity Treatment Leaders Refocus on Patient Experience

SHERIDAN, WYOMING – July 21, 2025 – Audrey Greenberg, known for transforming the cell and gene therapy manufacturing landscape, has embarked on a new chapter as partner at Mayo Clinic’s newly established venture arm. Her move follows a career of strategic pivots across finance, real estate, and biomanufacturing — each driven by an unwavering focus on creating meaningful impact.

From Wall Street to Purpose-Driven Ventures

Greenberg’s professional journey began on Wall Street, a path she reconsidered after witnessing the 9/11 attacks firsthand. "I watched the towers fall, and I thought, what do I want to do that actually makes an impact on society, instead of just moving other people’s money around?" she reflected. This question led her to launch a real estate venture focused on tax credit housing, developing shelters for battered women and affordable housing for seniors in underserved communities.

SHERIDAN, WYOMING – July 21, 2025 – Sarepta Therapeutics has entered a critical phase of uncertainty after reports surfaced that the U.S. Food and Drug Administration (FDA) is considering requesting a halt to all shipments of its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys. The potential move follows the disclosure of a third patient death associated with the company's underlying gene therapy platform.

FDA Scrutiny Intensifies After Third Death Linked to Platform